esomeprazole
Trade name: nexium
Approved
Feb 20, 2001
Esomeprazole, sold under the brand name Nexium [or Neksium] among others, is a medication which reduces stomach acid. It is used to treat gastroesophageal reflux disease, peptic ulcer disease, and Zollinger–Ellison syndrome. Its effectiveness is similar to that of other proton pump inhibitors (PPIs). It is taken by mouth or injection into a vein. — Wikipedia
Clinical trial activity
460 trials · 329 clinical orgs · 49 marketing orgs
Earliest trial started Dec 1, 1998 (NCT00473980)
Timeline
2000s
- Jan 1, 2000
AstraZeneca — Earliest Phase 3 Sponsor(trial)
- Feb 20, 2001
AstraZeneca — Earliest FDA Approval
- Feb 20, 2001
AstraZeneca — Marketing Organization
- Feb 20, 2001
AstraZeneca — NDA Organization
- Jan 1, 2002
AstraZeneca — Earliest Phase 2 Sponsor(trial)
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
2010s
- Apr 30, 2010
Horizon Pharma — Marketing Organization
- Apr 30, 2010
Horizon Pharma — NDA Secondary Org
- Aug 6, 2013
R2 Pharma LLC — NDA Secondary Org
- Aug 6, 2013
Belcher Pharmaceuticals — Marketing Organization
- Aug 6, 2013
Hanmi Pharmaceutical — Marketing Organization
- Aug 6, 2013
Belcher Pharmaceuticals — NDA Secondary Org
- Jan 26, 2015
Teva — Marketing Organization
- Aug 3, 2015
Mylan — Marketing Organization
- Sep 21, 2015
Hetero Labs Ltd — Marketing Organization
- Sep 25, 2015
Accord Research — Marketing Organization
- Sep 25, 2015
Dr. Reddy's Laboratories — Marketing Organization
- Oct 19, 2015
Torrent Pharmaceuticals Limited — Marketing Organization
- Apr 21, 2016
Aurobindo Pharma — Marketing Organization
- Aug 10, 2016
Eugia Pharma — Marketing Organization
- Mar 6, 2017
Deva Holding A.S. — Marketing Organization
- May 17, 2017
PHARMOBEDIENT — Marketing Organization
- Aug 18, 2017
Perrigo — Marketing Organization
- Sep 1, 2017
Lannett Company, Inc. — Marketing Organization
- Oct 20, 2017
Alkem Labs Ltd — Marketing Organization
- Apr 30, 2018
Sun Pharmaceuticals — Marketing Organization
- May 18, 2018
Sunshine Lake Pharma Co., Ltd. — Marketing Organization
- Mar 5, 2019
P&L Development — Marketing Organization
- Mar 5, 2019
Actavis — Marketing Organization
- Apr 10, 2019
Amneal Pharmaceuticals — Marketing Organization
- May 10, 2019
Glenmark Pharmaceuticals — Marketing Organization
- May 22, 2019
Zydus Discovery DMCC — Marketing Organization
2020s
- Mar 23, 2020
Cipla — Marketing Organization
- Apr 1, 2020
Gland Pharma Ltd — Marketing Organization
- Apr 1, 2020
Fosun — Marketing Organization
- Sep 22, 2020
Cisen Pharmaceutical — Marketing Organization
- Oct 2, 2020
Shijiazhuang Pharma Group (CSPC) — Marketing Organization
- Oct 20, 2020
Dexcel Pharma Technologies Ltd. — Marketing Organization
- Oct 20, 2020
Dexcel Pharma Technologies Ltd. — NDA Secondary Org
- Nov 18, 2020
Amta — Marketing Organization
- Nov 18, 2020
GUANGZHOU NOVAKEN — Marketing Organization
- Feb 26, 2021
Indchemie Health — Marketing Organization
- Mar 19, 2021
Graviti Pharmaceuticals — Marketing Organization
- Mar 31, 2021
Ethypharm — Marketing Organization
- Feb 10, 2022
Hainan Poly Pharm — Marketing Organization
- Feb 10, 2022
SLATE RUN PHARMA — Marketing Organization
- Aug 24, 2022
AbbVie — Marketing Organization
- Oct 6, 2022
Ajanta Pharma Ltd — Marketing Organization
- Mar 15, 2023
Guardian Drug — Marketing Organization
- Mar 15, 2023
ANDA Repository — Marketing Organization
- Mar 28, 2023
Prinston Inc — Marketing Organization
- Sep 29, 2023
Marksans Pharma — Marketing Organization
- Oct 11, 2023
Sciegen Pharmaceticals — Marketing Organization
- Oct 18, 2023
Granules India — Marketing Organization
- Dec 27, 2023
Zhejiang Yongtai — Marketing Organization
- Oct 23, 2024
Macleods Pharmaceuticals, Ltd — Marketing Organization
- Jan 8, 2025
Epic Pharma Llc — Marketing Organization
Indications
Approved for
Studied for
- Abdominal Pain · Phase 4
- Achlorhydria · Phase 1
- Acute Coronary Syndrome · Phase 4
- Airway Management · Phase 3
- Anastomotic Leak · Phase 4
- Anti-Inflammatory Agents, Non-Steroidal · Phase 3
- Arthritis · Phase 3
- Arthritis, Juvenile · Phase 4
- Arthritis, Rheumatoid · Phase 3
- Arthroplasty, Replacement, Knee · Phase 2
- Aspirin · Phase 4
- Asthma · Phase 3
- Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome · Phase 3
- Autism Spectrum Disorder · Phase 2
- Autistic Disorder · Phase 2
- Back Pain · Phase 3
- Bacterial Infections · Phase 4
- Bariatric Surgery · Phase 4
- Barrett Esophagus · Phase 4
- Bile Reflux · Phase 4
- Bismuth · Phase 4
- Bone and Bones · Phase 1
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Chest Pain · Phase 3
- Cholangiopancreatography, Endoscopic Retrograde · Phase 3
- Colorectal Neoplasms · Phase 4
- Coronary Artery Disease · Phase 4
- Cough · Phase 4
- Critical Illness · Phase 4
- Cystic Fibrosis · Phase 2
- Cytochrome P-450 CYP2C19 · Phase 4
- Deglutition Disorders · Phase 2
- Diabetes Mellitus, Type 1 · Phase 1
- Diabetes Mellitus, Type 2 · Phase 3
- Disease Eradication · Phase 1
- Drug Dosage Calculations · Phase 1
- Drug Interactions · Phase 1
- Drug Misuse · Phase 4
- Drug Resistance, Bacterial · Phase 3
- Drugs, Generic · Phase 1
- Drugs, Investigational · Phase 1
- Drug Therapy · Phase 4
- Dry Eye Syndromes · Phase 3
- Duodenal Ulcer · Phase 3
- Dyspepsia · Phase 4
- Eosinophilic Esophagitis · Phase 2/Phase 3
- Erb-b2 Receptor Tyrosine Kinases · Phase 1
- Esophageal Neoplasms · Phase 3
- Esophagitis · Phase 4
- Esophagitis, Peptic · Phase 4
- Estradiol · Phase 2/Phase 3
- Fasting · Phase 1
- Fatty Liver · Phase 1/Phase 2
- Gastric Acid · Phase 3
- Gastritis · Phase 4
- Gastritis, Atrophic · Phase 4
- Gastrointestinal Diseases · Phase 3
- Gastrointestinal Hemorrhage · Phase 3
- Gastrointestinal Stromal Tumors · Phase 4
- General Surgery · Phase 4
- Gram-Negative Bacterial Infections · Phase 2
- Graves Ophthalmopathy · Phase 3
- Head and Neck Neoplasms · Phase 2
- Healthy Volunteers · Phase 4
- Heartburn · Phase 4
- Helicobacter · Phase 4
- Helicobacter Infections · Phase 4
- Helicobacter pylori · Phase 4
- Hemorrhage · Phase 4
- Hepatitis B, Chronic · Phase 1
- HIV · Phase 3
- Homeostasis · Phase 1
- Hot Flashes · Phase 1
- Hypertension, Portal · Phase 4
- Hypertension, Pulmonary · Phase 1
- Ileostomy · Phase 1/Phase 2
- Infant, Premature · Phase 4
- Inflammation · Phase 3
- Intestinal Neoplasms · Phase 4
- Joint Diseases · Phase 2
- Laryngeal Diseases · Phase 3
- Laryngitis · Phase 4
- Laryngopharyngeal Reflux · Phase 4
- Liver Cirrhosis · Phase 4
- Low Back Pain · Phase 3
- Lung Diseases · Phase 3
- Lung Diseases, Obstructive · Phase 3
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 1
- Medicine, Chinese Traditional · Phase 1
- Multiple Sclerosis, Relapsing-Remitting · Phase 4
- Mutation · Phase 1
- Myocardial Infarction · Phase 4
- Nausea · Phase 4
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 1
- Neuralgia · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 1/Phase 2
- Obesity · Phase 4
- Obesity, Morbid · Phase 4
- Osteoarthritis · Phase 4
- Osteoporosis · Phase 4
- Pain · Phase 4
- Pancreatitis, Chronic · Phase 1
- Peptic Ulcer · Phase 4
- Peptic Ulcer Hemorrhage · Phase 4
- Percutaneous Coronary Intervention · Phase 3
- Pharmacokinetics · Phase 1
- Pharmacology · Phase 1
- Platelet Aggregation Inhibitors · Phase 1
- Precancerous Conditions · Phase 3
- Pre-Eclampsia · Phase 4
- Premature Birth · Phase 1
- Proton Pump Inhibitors · Phase 4
- Psoriasis · Phase 4
- Pulmonary Arterial Hypertension · Phase 1
- Radiodermatitis · Phase 1/Phase 2
- Respiratory Aspiration · Phase 4
- Safety · Phase 1
- Schizophrenia · Phase 4
- Sepsis · Phase 3
- Sex · Phase 4
- Shock, Septic · Phase 3
- Signs and Symptoms · Phase 3
- Signs and Symptoms, Digestive · Phase 3
- Sleep Disorders, Intrinsic · Phase 4
- Stomach Diseases · Phase 4
- Stomach Neoplasms · Phase 4
- Stomach Ulcer · Phase 4
- Therapeutic Equivalency · Phase 1
- Tooth Abnormalities · Phase 4
- Tooth Erosion · Phase 1/Phase 2
- Treatment Outcome · Phase 3
- Ulcer · Phase 4
- Vasomotor System · Phase 1
- Volunteers · Phase 1
- Vomiting · Phase 4
- Voriconazole · Phase 1
Mechanism of action
- Potassium-transporting ATPaseINHIBITOR
Potassium-transporting ATPase inhibitor
Alpha subunit is likely binding site
- UnclearUnclear
Unclear unclear
Combination products
vimovo
with naproxen
Also known as hcp1004, rld2401
Approval history
- approvedPriority reviewFeb 20, 2001
Chemistry & pharmacology
SMILES
COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.[Na+]- Mol. weight
- 367.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaEsomeprazole ↗
- NCATSN3PA6559FT ↗
- ChEMBLCHEMBL2146133 ↗
- ChEMBLCHEMBL2105294 ↗
- ChEMBLCHEMBL5314366 ↗
- ChEMBLCHEMBL1200470 ↗
- ChEMBLCHEMBL1201320 ↗
- ChEMBLCHEMBL2146140 ↗
Also known as
- esomelone
- esomeprazol
- esomeprazol
- esomeprazole
- esomeprazole
- esomeprazole
- esomeprazole
- esomeprazole
- esomeprazole
- esomeprazole
- esomeprazole
- esomeprazole
- ésoméprazole
- ésoméprazole
- esomeprazole magnesium
- esomeprazole magnesium
- esomeprazole magnesium
- esomeprazole magnesium
- esomeprazole magnesium dihydrate
- esomeprazole magnesium dihydrate
- esomeprazole magnesium dihydrate
- esomeprazole magnesium dihydrate
- esomeprazole magnesium dihydrate
- esomeprazole magnesium dihydrate
- esomeprazole magnesium hydrate
- esomeprazole magnesium hydrate
- esomeprazole (magnesium trihydrate)
- esomeprazole mg
- esomeprazole sodium
- esomeprazole sodium
- esomeprazole sodium
- esomeprazole sodium
- esomeprazole (sodium)
- esomeprazole strontium
- esomeprazole strontium
- esomeprazole strontium
- esomeprazole strontium
- esomeprazolum
- esomeprazolum
- fm0f67
- fm0f67
- h199/18 magnesium trihydrate
- h199/18 magnesium trihydrate
- h199/18 sodium
- h199/18 sodium
- nexium
- nexium
- nexium
- nexium
- nexium control
- nexium control
- nexium control
- nexium iv
- nexium iv
- nexium i.v.
- (-)-omeprazole
- perprazole
- perprazole
- (s)-esomeprazole
- (s)-omeprazole
- (s)-omeprazole
- (s)-omeprazole
- (s)-(−)-omeprazole
- (s)-(−)-omeprazole
- ventra
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07312370 | Phase 4 | Jan 20, 2026 | LanZhou University |
| NCT07248722 | N/A | Dec 31, 2025 | People's Liberation Army of China |
| NCT07139366 | Phase 4 | Sep 30, 2025 | People's Liberation Army of China |
| NCT07294846 | Phase 1 | Sep 8, 2025 | Sinorda Biomedicine |
| NCT07144657 | Phase 2 | Sep 1, 2025 | National Taiwan University |
| NCT07018635 | Phase 1 | Jul 16, 2025 | Incyte |
| NCT07268820 | Phase 4 | Jul 7, 2025 | Incheon St.Mary's Hospital |
| NCT06953986 | N/A | Jun 7, 2025 | Asian Institute of Gastroenterology |
| NCT06955520 | N/A | Apr 30, 2025 | Asian Institute of Gastroenterology |
| NCT06903585 | Phase 2 | Apr 30, 2025 | American University of Beirut |
| NCT06959368 | Phase 4 | Mar 25, 2025 | Asian Institute of Gastroenterology |
| NCT06851468 | N/A | Mar 15, 2025 | Government of China |
| NCT06783257 | Phase 2 | Feb 28, 2025 | Shandong New Time Pharmaceutical Co., LTD |
| NCT06811207 | Phase 3 | Feb 1, 2025 | Chang Gung University |
| NCT06793943 | Phase 1 | Jan 23, 2025 | Takeda |
| NCT06733675 | Phase 1 | Jan 7, 2025 | Department of Health and Human Services, VenatoRx Pharmaceuticals, Inc. |
| NCT06720610 | Phase 4 | Dec 9, 2024 | University of Indonesia |
| NCT06850480 | Phase 3 | Dec 5, 2024 | Livzon Pharmaceutical Group Inc. |
| NCT06717269 | Phase 1 | Nov 30, 2024 | Nurix Therapeutics, Inc. |
| NCT06595004 | Phase 3 | Nov 20, 2024 | Hanmi Pharmaceutical |
Organizations
Research & Development (329)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 109 | 92 | 5 | 2000 |
| Seoul National University | Academic/Hospital | 16 | 6 | 5 | 2003 |
| Jiao Tong University | Academic/Hospital | 15 | 13 | 1 | 2010 |
| People's Liberation Army of China | Government | 13 | 12 | 2 | 2014 |
| POZEN | For profit | 13 | 11 | 2 | 2007 |
| IQVIA | For profit | 10 | 0 | 3 | 2008 |
| Takeda | For profit | 10 | 10 | 3 | 2007 |
| Chinese University of Hong Kong | Academic/Hospital | 9 | 8 | 3 | 2002 |
| Kaohsiung Medical University | Academic/Hospital | 9 | 3 | 2 | 2007 |
| National Taiwan University | Academic/Hospital | 9 | 9 | 4 | 2004 |
| The University of Hong Kong | Academic/Hospital | 9 | 8 | 3 | 2003 |
| Shandong University | Academic/Hospital | 8 | 7 | 2 | 2013 |
| Yonsei University | Academic/Hospital | 8 | 4 | 3 | 2013 |
| CJ HealthCare Corp. | For profit | 7 | 7 | 4 | 2011 |
| Hanmi Pharmaceutical | For profit | 7 | 7 | 2 | 2018 |
| Chang Gung University | Academic/Hospital | 6 | 5 | 3 | 2010 |
| Chong Kun Dang Pharmaceutical | For profit | 6 | 6 | 2 | 2017 |
| Livzon Pharmaceutical Group Inc. | For profit | 6 | 6 | 3 | 2010 |
| Pfizer | For profit | 6 | 6 | 3 | 2008 |
| Taichung Veterans General Hospital | Academic/Hospital | 6 | 5 | 3 | 2007 |
Marketing (64)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ANDA Repository | For profit | MKTG | Mar 15, 2023 |
| AbbVie | For profit | MKTG | Aug 24, 2022 |
| Accord Research | For profit | MKTG | Sep 25, 2015 |
| Actavis | For profit | SYN | Aug 24, 2022 |
| Actavis | For profit | MKTG | Mar 5, 2019 |
| Ajanta Pharma Ltd | For profit | MKTG | Oct 6, 2022 |
| Alkem Labs Ltd | For profit | MKTG | Oct 20, 2017 |
| Amneal Pharmaceuticals | For profit | MKTG | Apr 10, 2019 |
| Amta | For profit | MKTG | Nov 18, 2020 |
| AstraZeneca | For profit | SYN | Feb 20, 2001 |
| AstraZeneca | For profit | MKTG | Feb 20, 2001 |
| AstraZeneca | For profit | NDA | Feb 20, 2001 |
| Aurobindo Pharma | For profit | SYN | Oct 16, 2017 |
| Aurobindo Pharma | For profit | MKTG | Apr 21, 2016 |
| Belcher Pharmaceuticals | For profit | MKTG | Aug 6, 2013 |
| Belcher Pharmaceuticals | For profit | NDA2 | Aug 6, 2013 |
| Cipla | For profit | MKTG | Mar 23, 2020 |
| Cisen Pharmaceutical | For profit | MKTG | Sep 22, 2020 |
| Deva Holding A.S. | For profit | MKTG | Mar 6, 2017 |
| Dexcel Pharma Technologies Ltd. | For profit | MKTG | Oct 20, 2020 |
| Dexcel Pharma Technologies Ltd. | For profit | SYN | Oct 20, 2020 |
| Dexcel Pharma Technologies Ltd. | For profit | NDA2 | Oct 20, 2020 |
| Dr. Reddy's Laboratories | For profit | SYN | Sep 25, 2015 |
| Dr. Reddy's Laboratories | For profit | MKTG | Sep 25, 2015 |
| Epic Pharma Llc | For profit | MKTG | Jan 8, 2025 |
| Ethypharm | For profit | MKTG | Mar 31, 2021 |
| Eugia Pharma | For profit | MKTG | Aug 10, 2016 |
| Fosun | For profit | MKTG | Apr 1, 2020 |
| GUANGZHOU NOVAKEN | For profit | MKTG | Nov 18, 2020 |
| Gland Pharma Ltd | For profit | MKTG | Apr 1, 2020 |
| Gland Pharma Ltd | For profit | SYN | Apr 1, 2020 |
| Glenmark Pharmaceuticals | For profit | MKTG | May 10, 2019 |
| Glenmark Pharmaceuticals | For profit | SYN | May 10, 2019 |
| Granules India | For profit | MKTG | Oct 18, 2023 |
| Graviti Pharmaceuticals | For profit | MKTG | Mar 19, 2021 |
| Guardian Drug | For profit | MKTG | Mar 15, 2023 |
| Hainan Poly Pharm | For profit | MKTG | Feb 10, 2022 |
| Hanmi Pharmaceutical | For profit | MKTG | Aug 6, 2013 |
| Hetero Labs Ltd | For profit | MKTG | Sep 21, 2015 |
| Horizon Pharma | For profit | MKTG | Apr 30, 2010 |
| Horizon Pharma | For profit | NDA2 | Apr 30, 2010 |
| Indchemie Health | For profit | MKTG | Feb 26, 2021 |
| Lannett Company, Inc. | For profit | MKTG | Sep 1, 2017 |
| Macleods Pharmaceuticals, Ltd | For profit | MKTG | Oct 23, 2024 |
| Marksans Pharma | For profit | MKTG | Sep 29, 2023 |
| Mylan | For profit | SYN | Aug 3, 2015 |
| Mylan | For profit | SYN | May 17, 2017 |
| Mylan | For profit | MKTG | Aug 3, 2015 |
| P&L Development | For profit | MKTG | Mar 5, 2019 |
| PHARMOBEDIENT | For profit | MKTG | May 17, 2017 |
| Perrigo | For profit | MKTG | Aug 18, 2017 |
| Prinston Inc | For profit | MKTG | Mar 28, 2023 |
| R2 Pharma LLC | For profit | NDA2 | Aug 6, 2013 |
| SLATE RUN PHARMA | For profit | MKTG | Feb 10, 2022 |
| Sciegen Pharmaceticals | For profit | MKTG | Oct 11, 2023 |
| Shijiazhuang Pharma Group (CSPC) | For profit | MKTG | Oct 2, 2020 |
| Sun Pharmaceuticals | For profit | SYN | Apr 30, 2018 |
| Sun Pharmaceuticals | For profit | SYN | Mar 18, 2013 |
| Sun Pharmaceuticals | For profit | MKTG | Apr 30, 2018 |
| Sunshine Lake Pharma Co., Ltd. | For profit | MKTG | May 18, 2018 |
| Teva | For profit | MKTG | Jan 26, 2015 |
| Torrent Pharmaceuticals Limited | For profit | MKTG | Oct 19, 2015 |
| Zhejiang Yongtai | For profit | MKTG | Dec 27, 2023 |
| Zydus Discovery DMCC | For profit | MKTG | May 22, 2019 |